{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:30:09Z","timestamp":1761514209409,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81100445"],"award-info":[{"award-number":["81100445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Administration of Hospitals Youth Program","award":["QML20151301"],"award-info":[{"award-number":["QML20151301"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6755.15015"],"award-info":[{"award-number":["320.6755.15015"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00404-018-4791-8","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T08:23:03Z","timestamp":1526977383000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy"],"prefix":"10.1007","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-7370","authenticated-orcid":false,"given":"Cheng-Juan","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"4791_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajog.2015.08.020.e1-e9","volume":"214","author":"O Mor","year":"2016","unstructured":"Mor O, Stavsky M, Yitshak-Sade M, Mastrolia SA, Beer-Weisel R, Rafaeli-Yehudai T, Besser L, Hamou B, Mazor M, Erez O (2016) Early onset preeclampsia and cerebral palsy: a double hit model? Am J Obstet Gynecol 214:105. \n                    https:\/\/doi.org\/10.1016\/j.ajog.2015.08.020.e1-e9","journal-title":"Am J Obstet Gynecol"},{"key":"4791_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/ajh.2010.105","volume":"23","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, Collier D, Cruickshank JK, Sever PS, Feder G, ASCOT (2010) Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens 23:1023\u20131030. \n                    https:\/\/doi.org\/10.1038\/ajh.2010.105","journal-title":"Am J Hypertens"},{"issue":"9242","key":"4791_CR3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/s0140-6736(00)03167-6","volume":"356","author":"Urs A Meyer","year":"2000","unstructured":"Meyer Urs A (2000) Pharmacogenetics and adverse drug reactions. The Lancet 356(9242):1667\u20131671. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(00)03167-6","journal-title":"The Lancet"},{"issue":"2","key":"4791_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.farma.2010.05.006","volume":"35","author":"MJ Rodr\u00edguez Arcas","year":"2011","unstructured":"Rodr\u00edguez Arcas MJ, Garc\u00eda-Jim\u00e9nez E, Mart\u00ednez-Mart\u00ednez F, Conesa-Zamora P (2011) Role of CYP450 in harmacokinetics and pharmacogenetics of antihypertensive drugs. Farm Hosp 35(2):84\u201392. \n                    https:\/\/doi.org\/10.1016\/j.farma.2010.05.006","journal-title":"Farm Hosp"},{"issue":"7","key":"4791_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1389200217666160524143843","volume":"17","author":"R Yang","year":"2016","unstructured":"Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, Li Y, Wang H, Chen L, Wu M, Zhao H (2016) Drug interactions with angiotensin receptor blockers: role of human cytochromes P450. Curr Drug Metab 17(7):681\u2013691. \n                    https:\/\/doi.org\/10.2174\/1389200217666160524143843","journal-title":"Curr Drug Metab"},{"issue":"4","key":"4791_CR6","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/aog.0000000000002019","volume":"129","author":"Committee on Obstetric Practice","year":"2017","unstructured":"Committee on Obstetric Practice (2017) Committee opinion no. 692: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol 129(4):e90\u2013e95. \n                    https:\/\/doi.org\/10.1097\/aog.0000000000002019","journal-title":"Obstet Gynecol"},{"key":"4791_CR7","unstructured":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (UK) (2010) Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. National Institute for Health and Clinical Excellence: Guidance, RCOG Press, London. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK62652"},{"key":"4791_CR8","doi-asserted-by":"publisher","first-page":"215.e1\u2013e6","DOI":"10.1016\/j.ajog.2012.12.031","volume":"208","author":"DM Haas","year":"2013","unstructured":"Haas DM, Dantzer J, Lehmann AS, Philips S, Skaar TC, McCormick CL, Hebbring SJ, Jung J, Li L (2013) The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration. Am J Obstet Gynecol 208:215.e1\u2013e6. \n                    https:\/\/doi.org\/10.1016\/j.ajog.2012.12.031","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"4791_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/0002-9378(90)90386-L","volume":"162","author":"RC Rogers","year":"1990","unstructured":"Rogers RC, Sibai BM, Whybrew WD (1990) Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol 162(2):362\u2013366","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"4791_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2217\/pgs.09.153","volume":"11","author":"A Alfirevic","year":"2010","unstructured":"Alfirevic A, Alfirevic Z, Pirmohamed M (2010) Pharmacogenetics in reproductive and perinatal medicine. Pharmacogenomics 11(1):65\u201379. \n                    https:\/\/doi.org\/10.2217\/pgs.09.153","journal-title":"Pharmacogenomics"},{"issue":"5","key":"4791_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/tpj.2016.35","volume":"17","author":"MR Luizon","year":"2016","unstructured":"Luizon MR, Palei ACT, Belo VA, Amaral LM, Lacchini R, Duarte G, Cavalli RC, Sandrim VC, Tanus-Santos JE (2016) Gene\u2013gene interactions in the NAMPT pathway, plasma visfatin\/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 17(5):427\u2013434. \n                    https:\/\/doi.org\/10.1038\/tpj.2016.35","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"4791_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00404-014-3475-2","volume":"291","author":"VC Sandrim","year":"2015","unstructured":"Sandrim VC, Palei AC, Eleuterio N, Tanus-Santos JE, Cavalli RC (2015) Antihypertensive therapy in pre-eclampsia is not modulated by VEGF polymorphisms. Arch Gynecol Obstet 291(4):799\u2013803. \n                    https:\/\/doi.org\/10.1007\/s00404-014-3475-2","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"4791_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/tpj.2014.26","volume":"14","author":"MR Luizon","year":"2014","unstructured":"Luizon MR, Palei AC, Sandrim VC, Amaral LM, Machado JS, Lacchini R, Cavalli RC, Duarte G, Tanus-Santos JE (2014) Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 14(6):535\u2013541. \n                    https:\/\/doi.org\/10.1038\/tpj.2014.26","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"4791_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1742-7843.2012.00905.x","volume":"111","author":"AC Palei","year":"2012","unstructured":"Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Lacchini R, Duarte G, Tanus-Santos JE (2012) Effects of matrix metalloproteinase (MMP)-2 polymorphisms on responsiveness to antihypertensive therapy of women with hypertensive disorders of pregnancy. Basic Clin Pharmacol Toxicol 111(4):262\u2013267. \n                    https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00905.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"4791_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/tpj.2011.31","volume":"12","author":"AC Palei","year":"2012","unstructured":"Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Lacchini R, Duarte G, Tanus-Santos JE (2012) Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 12(6):489\u2013498. \n                    https:\/\/doi.org\/10.1038\/tpj.2011.31","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"4791_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/tpj.2009.38","volume":"10","author":"VC Sandrim","year":"2010","unstructured":"Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE (2010) eNOS haplotypes affect the responsiveness to antihypertensive therapy in pre-eclampsia but not in gestational hypertension. Pharmacogenomics J 10(1):40\u201345. \n                    https:\/\/doi.org\/10.1038\/tpj.2009.38","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"4791_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2217\/pgs.13.228","volume":"15","author":"DM Haas","year":"2014","unstructured":"Haas DM (2014) Pharmacogenetics and individualizing drug treatment during pregnancy. Pharmacogenomics 15(1):69\u201378. \n                    https:\/\/doi.org\/10.2217\/pgs.13.228","journal-title":"Pharmacogenomics"},{"issue":"1","key":"4791_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1124\/dmd.112.046292","volume":"41","author":"T Cabaleiro","year":"2013","unstructured":"Cabaleiro T, Rom\u00e1n M, Ochoa D, Taleg\u00f3n M, Prieto-P\u00e9rez R, Wojnicz A, L\u00f3pez-Rodr\u00edguez R, Novalbos J, Abad-Santos F (2013) Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 41(1):224\u2013229. \n                    https:\/\/doi.org\/10.1124\/dmd.112.046292","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4791_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/paf.0b013e3180326701","volume":"28","author":"A Koski","year":"2007","unstructured":"Koski A, Ojanper\u00e4 I, Sistonen J, Vuori E, Sajantila A (2007) A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 28(3):259\u2013261. \n                    https:\/\/doi.org\/10.1097\/paf.0b013e3180326701","journal-title":"Am J Forensic Med Pathol"},{"issue":"1","key":"4791_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/paf.0b013e3180326701","volume":"32","author":"C Ribeiro","year":"2017","unstructured":"Ribeiro C, Martins P, Grazina M (2017) Genotyping CYP2D6 by three different methods: advantages and disadvantages. Drug Metab Pers Ther 32(1):33\u201337. \n                    https:\/\/doi.org\/10.1097\/paf.0b013e3180326701","journal-title":"Drug Metab Pers Ther"},{"key":"4791_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/249642","volume":"2013","author":"NNSBNM Kamal","year":"2013","unstructured":"Kamal NNSBNM, Lim TS, Tye GJ, Ismail R, Choong YS (2013) The Effect of CYP2B6, CYP2D6, and CYP3A4 alleles on methadone binding: A molecular docking study. J Chem 2013:1\u20137. \n                    https:\/\/doi.org\/10.1155\/2013\/249642","journal-title":"J Chem"},{"issue":"2","key":"4791_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/dmd.112.050245","volume":"41","author":"N Isoherranen","year":"2013","unstructured":"Isoherranen N, Thummel KE (2013) Drug metabolism and transport during pregnancy: how does drug disposition change duringpregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 41(2):256\u2013262. \n                    https:\/\/doi.org\/10.1124\/dmd.112.050245","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4791_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/jhh.2014.76","volume":"29","author":"V Fontana","year":"2015","unstructured":"Fontana V, Luizon MR, Sandrim VC (2015) An update on the pharmacogenetics of treating hypertension. J Hum Hypertens 29(5):283\u2013291. \n                    https:\/\/doi.org\/10.1038\/jhh.2014.76","journal-title":"J Hum Hypertens"},{"issue":"3","key":"4791_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/clpt.2010.279","volume":"89","author":"MV Relling","year":"2011","unstructured":"Relling MV, Klein TE (2011) CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89(3):464\u2013467. \n                    https:\/\/doi.org\/10.1038\/clpt.2010.279","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4791_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/01.fjc.0000184117.76188.68","volume":"46","author":"T Nozawa","year":"2005","unstructured":"Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H (2005) Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 46(5):713\u2013720 PMID:16220080","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"4791_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0009-9236(03)00068-7","volume":"74","author":"JA Johnson","year":"2003","unstructured":"Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF (2003) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74(1):44\u201352. \n                    https:\/\/doi.org\/10.1016\/s0009-9236(03)00068-7","journal-title":"Clin Pharmacol Ther"},{"key":"4791_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therap 138:103\u2013141. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Therap"},{"issue":"2","key":"4791_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ajhg.2007.10.002","volume":"82","author":"Stuart A Scott","year":"2008","unstructured":"Scott Stuart A, Edelmann L, Kornreich R, Desnick RJ (2008) Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82(2):495\u2013500. \n                    https:\/\/doi.org\/10.1016\/j.ajhg.2007.10.002","journal-title":"Am J Hum Genet"},{"key":"4791_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/00498254.2013.820007","volume":"44","author":"YH Wang","year":"2014","unstructured":"Wang YH, Pan PP, Dai DP, Wang SH, Geng PW, Cai JP, Hu GX (2014) Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Xenobiotica 44:270\u2013275. \n                    https:\/\/doi.org\/10.3109\/00498254.2013.820007","journal-title":"Xenobiotica"},{"issue":"6","key":"4791_CR30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2217\/pgs.13.23","volume":"14","author":"MR Luizon","year":"2013","unstructured":"Luizon MR, Sandrim VC (2013) Pharmacogenomic approaches that may guide pre-eclampsia therapy. Pharmacogenomics 14(6):591\u2013593. \n                    https:\/\/doi.org\/10.2217\/pgs.13.23","journal-title":"Pharmacogenomics"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-018-4791-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:48:45Z","timestamp":1559130525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-018-4791-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4791"],"URL":"https:\/\/doi.org\/10.1007\/s00404-018-4791-8","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"type":"print","value":"0932-0067"},{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"17 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sun Cheng-Juan declares that she has no conflict of interest. Li Lin declares that he has no conflict of interest. Li Xue-Yan declares that she has no conflict of interest. Zhang Wei-Yuan declares that he has no conflict of interest. Liu Xiao-Wei declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}